dronabinol has been researched along with Metabolic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hardy, DB; Lee, K | 1 |
| Appendino, G; Calzado, MA; Eugenia Prados, M; Ferreiro-Vera, C; Garrido-Rodriguez, M; Morrugares, R; Muñoz, E; Nadal, X; Palomares, B; Ruiz-Pino, F; Sánchez-Garrido, MA; Tena-Sempere, M; Vazquez, MJ; Velasco, I | 1 |
1 review(s) available for dronabinol and Metabolic Diseases
| Article | Year |
|---|---|
Metabolic Consequences of Gestational Cannabinoid Exposure.
Topics: Animals; Cannabinoid Receptor Agonists; Dronabinol; Female; Fetal Growth Retardation; Humans; Lipid Metabolism; Liver; Metabolic Diseases; Placenta; Pregnancy; Prenatal Exposure Delayed Effects | 2021 |
1 other study(ies) available for dronabinol and Metabolic Diseases
| Article | Year |
|---|---|
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity.
Topics: 3T3-L1 Cells; Adipogenesis; Adiposity; Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet, High-Fat; Dronabinol; Fatty Liver; HEK293 Cells; Humans; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone | 2020 |